Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2010 Q1- Text added to 2010 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Good
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
adult, ALK, allergic, allergy, anaplastic, assessed, back, Bayer, Calistoga, canceled, cohort, delta, distinct, Dr, dual, epidermal, escalation, factor, forecasted, gamma, gate, gene, GlaxoSmithKline, heavily, Hospital, immune, immunity, implicated, inflammation, inflammatory, Intellikine, intracellular, IST, kinase, landscape, Lecia, lymphoma, NIH, nonstatutory, Oncothyreon, optimal, patterning, percent, proportion, qualitative, quantitative, receptor, revert, rheumatoid, Semafore, Sequist, strongly, temporary, trafficking, transduction, twelve, unexercised, withdrawn
Valuein 2010 Q1 filing- Value in 2010 Q2 filing
Original filings
Filing view